六月 2026
- Home
- NS Pharma
六月 2026的NS Pharma市场份额分析
This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I’m a bike messenger […]
NS Pharma(包含公司地区分支机构)
查看更多网站流量和参与度信息- nspharma.com
NS Pharma收入截至 六月 2026为 10M - 15M
NS Pharma主要域名产生的收入
3 年中NS Pharma主要域名的收入
NS Pharma主要域名的收入
NS Pharma热门域名的总访问量
了解NS Pharma市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
NS Pharma热门域名的平均访问时长
分析NS Pharma参与度指标。
过去 3 个月的平均访问时长
子公司明细
NS Pharma热门域名的平均页面浏览量
了解NS Pharma如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
NS Pharma 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻NS Pharma, Inc. has issues with failing to "adequately prepare" for the commercial launch.According to Capricor, the distribution agreement with NS Pharma contains a "fundamental pricing flaw" that its partner has refused to address, and it has accused the company of failing to "adequately prepare" for the commercial launch.
五月 8, 2026阅读更多
新闻Capricor Therapeutics, Inc. files suit against NS Pharma, Inc..Capricor Therapeutics, Inc. (Headquarters: California, USA, CEO: Linda Marbán, NASDAQ: CAPR) announced that it has filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary, NS Pharma, Inc., seeking an injunction against the Commercialization and Distribution Agreement for CAP-1002 (deramiocel) (the Agreement).
五月 8, 2026阅读更多
新闻NS Pharma, Inc. signs new client U.S. Food and Drug Administration.NS Pharma Inc.'s NS-051 (NCNP-04) has been awarded orphan drug designation by the FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 51 skipping.
九月 22, 2025阅读更多
查看 NS Pharma 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
